Boston, United States
HotSpot Therapeutics, Inc., founded in 2017 and headquartered in the United States, is pioneering a new wave in drug discovery through its approach to developing allosteric therapies. The company’s slogan, "Discovering new allosteric therapies with the ability to treat disease in new ways", encapsulates its mission to transform disease treatment by targeting nature’s regulatory hotspots, which are crucial for protein function but distinct from active sites.
HotSpot's innovative platform focuses on these "hotspots" that are key to protein regulatory mechanisms, providing a unique edge in treating diseases with limited or no known therapies. Their approach offers increased selectivity and effective pharmacology compared to conventional medicines.
The company received a major boost with a $100.00M Series C investment in November 2021, attracting investment from prominent names like Atlas Venture, B Capital Group, and Sofinnova Partners, among others. This substantial investment underscores strong confidence in HotSpot's potential to redefine therapeutic strategies.
